The past six months have highlighted a major reshaping in neuroscience. While recent years have been characterised by incremental improvements in symptom control, 2026 is increasingly becoming the year of disease modification, precision medicine and patient-centred innovation. From the first approved orexin agonist in narcolepsy to blood-based biomarkers transforming Alzheimer’s diagnosis, neuroscience is moving toward treatments and technologies that address underlying biology rather than simply managing symptoms. This month, HRW Synapse explores five trends that are reshaping the future of neuroscience in 2026, and what they could mean for patients, healthcare professionals and the wider industry. Trend 1: Disease Modification Becomes the New Standard Historically, many neurological therapies have focused on controlling symptoms rather than altering disease progression. However, advancements are now designed to restore, replace or protect damaged neurological systems. This trend is visible across several therapy areas. -In Alzheimer’s Disease, Biogen’s diranersen generated growing excitement around tau-targeted disease modification despite missing its primary endpoint, with findings supporting advancement into Phase III development. -In epilepsy, Neurona’s NRTX-1001 cell therapy has delivered substantial and durable reductions in seizure frequency following a single administration. -Meanwhile, Parkinson’s disease is attracting renewed interest in restorative approaches, including stem-cell derived dopaminergic therapies intended to replace lost neurons. Rare neurological diseases are also benefiting from this shift. Companies continue to invest heavily in gene therapies, cell therapies and precision medicines targeting conditions with historically limited treatment options. Recent activity in Huntington’s disease, epilepsy and rare neuromuscular disorders demonstrates growing confidence that transformative outcomes may be achievable in areas once considered out of reach. Rather than simply helping patients live with disease, the industry’s ambition is increasingly focused on changing the course of disease itself. Trend 2: The Age of Orexins Has Begun Narcolepsy has long been managed using therapies that address individual symptoms such as excessive daytime sleepiness and cataplexy. However, recent developments suggest the field has entered a new era. The biggest development has been the emergence of orexin receptor agonists, a new class of therapies designed to replace the missing orexin signaling that underlies narcolepsy type 1. Takeda’s oveporexton became the first approved orexin agonist after Phase III studies demonstrated improvements across wakefulness, daytime functioning, cognition, cataplexy and night-time symptoms. Additional data also showed benefits extending beyond wakefulness alone, including improvements in fatigue, social functioning and overall quality of life. Momentum behind the class continues to build. Alkermes reported encouraging Phase II data for alixorexton, while Lilly strengthened its position through the acquisition of Centessa and its OX2R agonist program. Unlike traditional stimulants and wake-promoting agents, orexin agonists aim to address the biological cause of disease itself. As a result, they represent one of the clearest examples of neuroscience moving beyond symptom management toward mechanism-based treatment. Trend 3: Precision Medicine and Biomarkers Move Into Clinical Practice One of the most important scientific developments of 2026 has been the rapid advancement of biomarkers capable of identifying disease earlier and monitoring progression more accurately. Alzheimer’s Disease has been at the forefront of this movement. Following FDA clearance of blood-based Alzheimer’s tests, diagnostic tools are now beginning to enter routine primary care settings. Recent data presented at the Alzheimer’s Association International Conference demonstrated that blood biomarker testing can raise diagnostic accuracy among primary care physicians from 65% to more than 90%, approaching specialist-level performance. Researchers have also developed an “Alzheimer’s clock” capable of estimating the likely timing of symptom onset years before symptoms emerge. Similar trends are emerging elsewhere. In Multiple Sclerosis, neurofilament light chain blood testing is becoming an increasingly important tool for monitoring disease activity and treatment response. Together, these developments signal a shift away from relying solely on clinical symptoms and toward a future where diagnosis, prognosis and treatment selection are increasingly guided by objective biological markers. Trend 4: Convenience Becomes a Competitive Advantage While efficacy remains essential, treatment convenience is becoming a major differentiator across neuroscience. Companies are increasingly recognizing that reducing treatment burden can improve access, adherence and patient experience. In neuroimmunology, several recent developments reflect this trend. Regeneron’s cemdisiran has the potential to offer quarterly dosing for generalized Myasthenia Gravis (gMg), while Argenx expanded Vyvgart’s use across the broader adult gMG population. New self-administration options have also emerged, including a pre-filled pen presentation in gMG. Alzheimer’s Disease is seeing similar changes. The FDA recently approved the first at-home subcutaneous initiation option for Leqembi, reducing reliance on infusion centers and potentially expanding patient access. These advances demonstrate that innovation is no longer defined solely by new mechanisms of action. Increasingly, success will depend on making treatments easier to access, administer and integrate into everyday life. Trend 5: Alzheimer’s Beyond Amyloid Perhaps the most interesting scientific discussion of 2026 has centered on Alzheimer’s Disease. A major systematic review questioned whether anti-amyloid antibodies deliver meaningful clinical benefits and highlighted the associated risks of ARIA-related brain swelling and bleeding. The findings have intensified skepticism about whether amyloid removal alone is sufficient to alter disease progression. At the same time, researchers continue to uncover new biological targets and pathways, including tau pathology, metabolic drivers, inflammatory mechanisms and novel protein targets. Blood biomarkers are improving diagnostic accuracy, while tau-directed therapies are generating renewed excitement across the field. Rather than signaling the end of disease modification in Alzheimer’s Disease, these developments suggest the field may be entering a more sophisticated era in which multiple biological pathways contribute to both diagnosis and treatment. Looking Ahead Taken together, the developments of 2026 suggest neuroscience is entering a period of significant transformation. Disease-modifying therapies are becoming a reality, biomarkers are enabling more precise care, and patient convenience is emerging as a critical driver of innovation. Whether through orexin replacement in narcolepsy, cell therapies in epilepsy or blood-based diagnostics in Alzheimer’s Disease, the industry is increasingly focused on understanding and addressing the biology underlying neurological disease. If you’d like to find out more about how these trends are changing the industry, and what these implications mean for your project, fill in the Contact form below. Apply Now!